BONE Bows Out Of Big Board, HALO Shines, MabVax On Watch, TRIV Revises Outlook

(RTTNews) - Bacterin International Holdings Inc. (BONE) is all set to be suspended from the NYSE MKT and move to the OTCQX(R) marketplace for non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE MKT Company Guide.

- Section 1003(a)(i) requires a company to maintain at least $2 million in stockholders' equity if a company has sustained losses from continuing operations and/or net losses in two of its three most recent fiscal years.

- Section 1003(a)(ii) requires a company to maintain at least $4 million in stockholders' equity if the company has reported losses from continuing operations and net losses in three out of its four most recent fiscal years.

- Section 1003(a)(ii) of the Company Guide requires a company to maintain at least $4 million in stockholders' equity if the company has reported losses from continuing operations and net losses in three out of its four most recent fiscal years.

BONE closed Tuesday's trading at $4.23, up 0.71%.

Halozyme Therapeutics Inc. (HALO) is planning to proceed with a phase III clinical study of its investigational new drug PEGPH20 in patients with metastatic pancreatic cancer, using a design allowing for potential marketing application based on either progression free survival or overall survival. This decision follows a Type B meeting, which the company had with the FDA recently.

Based on the FDA feedback, the company is targeting the end of first quarter 2016 to initiate the phase III study.

A phase II multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer, initiated by the company in the second quarter of 2013, and a phase 1b/2 randomized clinical trial of PEGPH20 in combination with modified FOLFIRINOX chemotherapy compared to mFOLFIRINOX treatment alone in patients with metastatic pancreatic adenocarcinoma, initiated by SWOG, a cancer research cooperative group, in October 2013 are underway.

HALO closed Wednesday's trading 4.51% higher at $15.28.

Inovio Pharmaceuticals Inc. (INO) has been selected to receive a grant from the Defense Advanced Research Projects Agency, or DARPA, to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.

Inovio is the prime contractor on the $45 million DARPA program, which also includes MedImmune, the global biologics research and development arm of AstraZeneca; GeneOne Life Sciences and its manufacturing subsidiary, VGXI, Inc.; and Professor David B. Weiner, PhD, professor of Pathology and Laboratory Medicine at The Perelman School of Medicine at the University of Pennsylvania, Emory University and Vanderbilt University.

In previously published preclinical testing, Inovio's DNA-based Ebola vaccine protected 100% of vaccinated animals from death and sickness after being exposed to a lethal dose of the Ebola virus. The company's DNA-based vaccine against Ebola, with the first patient is expected to be dosed in this quarter (2Q 2015).

The 2014 Ebola epidemic, which mostly affected multiple countries in West Africa, is the largest in history which resulted in 10,311 deaths.

INO closed Wednesday's trading at $9.72, up 7.05%. In after-hours, the stock gained another 6.28% to $10.33.

Shares of MabVax Therapeutics Holdings Inc. (MBVX.OB) have gained over 37% in the past three days following news of $12 million investment in the company by billionaire Bio-Pharma Investor Dr. Phillip Frost and his company OPKO Health (OPK) on April 6, 2015.

MabVax intends to use the proceeds from the financing to initiate phase 1 trials for its HuMab 5B1 antibody later this year and to further advance other novel human antibodies in its pipeline. The HuMab 5B1 antibody is being developed as both a diagnostic and therapeutic product targeting pancreatic and colon cancer.

In addition, MabVax currently has advanced phase II trials ongoing for its recurrent sarcoma and ovarian cancer vaccines, and patient survival results are expected in the first half of 2016.

MBVX.OB closed Wednesday's trading 15.81% higher at $3.59.

TriVascular Technologies Inc. (TRIV) has revised its revenue forecast downward for 2015, taking into account the market dynamics, seasonality, and currency exchange rates.

Accordingly, the company now anticipates total revenue for full-year 2015 to be in the range of $36 to $39 million, down from its earlier forecast of $45 million to $49 million. The company's total revenue in 2014 was to $31.8 million.

TriVascular is slated to reports its complete first quarter results after the close of the market on May 5, 2015. The company has projected total revenue of approximately $8.0 million for the first quarter of 2015, which is less than Wall Street estimates of $9.37 million, but an increase of 14.1% from the first quarter of 2014.

TRIV closed Tuesday's trading at $10.07, down 0.10%.